-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Autoimmune diseases are generally considered to be both organ-specific and systemic diseases that occur primarily as a result of a malfunction of the immune system that mistakenly attacks one's own cells and tissues
.
About 8%-10% of the population is affected by autoimmune diseases, which cause serious injury, high mortality, and high medical costs
.
Although existing treatments, such as small molecule and antibody drugs, help slow disease progression and reduce disability, they cause serious side effects and do not reverse disease manifestations
.
Therefore, finding new innovative therapeutic methods and drug molecules is the primary goal of translational medicine research at present
.
On March 28, 2022, Wang Honglin's team from the Clinical Research Institute of the First People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine/Precision Research Center for Difficult Diseases published a paper entitled "A peptide encoded by pri-miRNA-31 represses autoimmunity by the classic journal EMBO reports.
The original research results of promoting Treg differentiation”, the paper reports that the non-coding RNA that is traditionally thought to have no coding function: miR-31 precursor can encode a polypeptide of 44 amino acids in length and named it micro-polypeptide 31 (miPEP31)
.
The researchers first confirmed that the miR-31 precursor also has the ability to encode polypeptides through technologies such as Ribosome fingerprint, Mass spectrum and Western blot
.
miPEP31 is highly expressed in Treg cells and can promote the differentiation of Treg cells
.
miPEP31 has very good transmembrane properties and can efficiently enter immune cells in vitro
.
And in vivo experiments, a single tail vein injection can significantly increase the level of miPEP31 in immune cells and maintain it for more than 48 hours
.
miPEP31 has excellent therapeutic effect on the experimental encephalomyelitis model of autoimmune disease mouse model
.
Mechanistically, miPEP31 can enter the nucleus and inhibit the translation of miR-31 precursors by binding to the promoter region of miR-31 and affecting histone epigenetic modifications in the promoter region
.
It reduces the expression of miPEP31 and miR-31 in a negative feedback manner, thereby promoting the differentiation of Treg cells and maintaining the immune balance of the body
.
This study revealed a new mechanism by which non-coding RNAs regulate autoimmunity, and provided innovative ideas and methods for the clinical treatment of autoimmune diseases
.
miPEP31 has good safety, and its transmembrane properties make it have better targeting and drug potential, providing a new strategy for clinical treatment of autoimmune diseases
.
Many properties of polypeptide drugs are between chemical drugs and protein drugs.
They have the advantages of high activity and safety, strong specificity, and good druggability.
They are widely used in clinical practice and have broad prospects
.
In recent years, peptides have attracted more and more attention as therapeutic drugs
.
Efficacy, safety and targeting are the biggest difficulties faced in the development of peptide drugs
.
Recent studies have shown that non-coding RNAs that traditionally do not have coding functions have the ability to encode polypeptides
.
More than 210,000 non-coding RNAs have been found in the human genome, far exceeding the number of protein genes (about 20,000)
.
Endogenous non-coding RNA-encoded polypeptides in vivo have natural safety and efficacy, and are a new strategy for researching polypeptide drugs
.
Wang Honglin's team has accumulated rich experience and achieved a series of achievements in the field of exploration of polypeptides encoded by non-coding regions of the genome
.
The team published an article entitled "A micropeptide encoded by lncRNA MIR155HG suppresses autoimmune inflammation via modulating antigen presentation" in the well-known journal Science Advance in May 2020
.
This study found that non-coding RNA: MIR155HG can encode the polypeptide miPEP155 and affect the antigen presentation function of dendritic cells by binding to HSP70; miPEP155 has a good therapeutic effect on mouse psoriasis-like models and experimental encephalomyelitis models
.
The above-mentioned miPEP31 and miPEP155 are both the peptide drug candidates discovered and named by the team for the first time in the world.
They have obtained the national invention patent authorization (ZL201610139849.
6; ZL201810643349.
5), and have strong translational medicine research potential
.
The first author of the paper is Zhou Hong, an assistant researcher in Wang Honglin's team, and Li Qun, a teacher from the affiliated Ruijin Hospital, is the co-corresponding author
.
The research was strongly supported by the School of Basic Medicine of Shanghai Jiao Tong University School of Medicine and the Shanghai Institute of Immunology
.
The research was supported by the National Natural Science Foundation of China Original Exploration Program (No.
82050009), the National Key Research and Development Program of the Ministry of Science and Technology (2020YFA0112900), the National Science Fund for Distinguished Young Scholars (No.
81725018), the National Natural Science Foundation of China Key Project (No.
81930088), General Program of Natural Science Foundation of China (No.
82070509, No.
82073428), Youth Program of National Natural Science Foundation of China (No.
82101909, No.
82103719), Shenkang Medical Development Center's Three-Year Action Plan for Promoting Clinical Skills and Clinical Innovation in Municipal Hospitals The clinical "five new" innovative research and development project (SHDC2020CR3061B), and the Natural Science Foundation of Shanghai Science and Technology Commission (20ZR1447400)
.
Link to the original text: https:// Wang Honglin's research group recruits postdoctoral fellows all the year round.
If you are interested, please contact: honglin.
wang@sjtu.
edu.
cn
.
About 8%-10% of the population is affected by autoimmune diseases, which cause serious injury, high mortality, and high medical costs
.
Although existing treatments, such as small molecule and antibody drugs, help slow disease progression and reduce disability, they cause serious side effects and do not reverse disease manifestations
.
Therefore, finding new innovative therapeutic methods and drug molecules is the primary goal of translational medicine research at present
.
On March 28, 2022, Wang Honglin's team from the Clinical Research Institute of the First People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine/Precision Research Center for Difficult Diseases published a paper entitled "A peptide encoded by pri-miRNA-31 represses autoimmunity by the classic journal EMBO reports.
The original research results of promoting Treg differentiation”, the paper reports that the non-coding RNA that is traditionally thought to have no coding function: miR-31 precursor can encode a polypeptide of 44 amino acids in length and named it micro-polypeptide 31 (miPEP31)
.
The researchers first confirmed that the miR-31 precursor also has the ability to encode polypeptides through technologies such as Ribosome fingerprint, Mass spectrum and Western blot
.
miPEP31 is highly expressed in Treg cells and can promote the differentiation of Treg cells
.
miPEP31 has very good transmembrane properties and can efficiently enter immune cells in vitro
.
And in vivo experiments, a single tail vein injection can significantly increase the level of miPEP31 in immune cells and maintain it for more than 48 hours
.
miPEP31 has excellent therapeutic effect on the experimental encephalomyelitis model of autoimmune disease mouse model
.
Mechanistically, miPEP31 can enter the nucleus and inhibit the translation of miR-31 precursors by binding to the promoter region of miR-31 and affecting histone epigenetic modifications in the promoter region
.
It reduces the expression of miPEP31 and miR-31 in a negative feedback manner, thereby promoting the differentiation of Treg cells and maintaining the immune balance of the body
.
This study revealed a new mechanism by which non-coding RNAs regulate autoimmunity, and provided innovative ideas and methods for the clinical treatment of autoimmune diseases
.
miPEP31 has good safety, and its transmembrane properties make it have better targeting and drug potential, providing a new strategy for clinical treatment of autoimmune diseases
.
Many properties of polypeptide drugs are between chemical drugs and protein drugs.
They have the advantages of high activity and safety, strong specificity, and good druggability.
They are widely used in clinical practice and have broad prospects
.
In recent years, peptides have attracted more and more attention as therapeutic drugs
.
Efficacy, safety and targeting are the biggest difficulties faced in the development of peptide drugs
.
Recent studies have shown that non-coding RNAs that traditionally do not have coding functions have the ability to encode polypeptides
.
More than 210,000 non-coding RNAs have been found in the human genome, far exceeding the number of protein genes (about 20,000)
.
Endogenous non-coding RNA-encoded polypeptides in vivo have natural safety and efficacy, and are a new strategy for researching polypeptide drugs
.
Wang Honglin's team has accumulated rich experience and achieved a series of achievements in the field of exploration of polypeptides encoded by non-coding regions of the genome
.
The team published an article entitled "A micropeptide encoded by lncRNA MIR155HG suppresses autoimmune inflammation via modulating antigen presentation" in the well-known journal Science Advance in May 2020
.
This study found that non-coding RNA: MIR155HG can encode the polypeptide miPEP155 and affect the antigen presentation function of dendritic cells by binding to HSP70; miPEP155 has a good therapeutic effect on mouse psoriasis-like models and experimental encephalomyelitis models
.
The above-mentioned miPEP31 and miPEP155 are both the peptide drug candidates discovered and named by the team for the first time in the world.
They have obtained the national invention patent authorization (ZL201610139849.
6; ZL201810643349.
5), and have strong translational medicine research potential
.
The first author of the paper is Zhou Hong, an assistant researcher in Wang Honglin's team, and Li Qun, a teacher from the affiliated Ruijin Hospital, is the co-corresponding author
.
The research was strongly supported by the School of Basic Medicine of Shanghai Jiao Tong University School of Medicine and the Shanghai Institute of Immunology
.
The research was supported by the National Natural Science Foundation of China Original Exploration Program (No.
82050009), the National Key Research and Development Program of the Ministry of Science and Technology (2020YFA0112900), the National Science Fund for Distinguished Young Scholars (No.
81725018), the National Natural Science Foundation of China Key Project (No.
81930088), General Program of Natural Science Foundation of China (No.
82070509, No.
82073428), Youth Program of National Natural Science Foundation of China (No.
82101909, No.
82103719), Shenkang Medical Development Center's Three-Year Action Plan for Promoting Clinical Skills and Clinical Innovation in Municipal Hospitals The clinical "five new" innovative research and development project (SHDC2020CR3061B), and the Natural Science Foundation of Shanghai Science and Technology Commission (20ZR1447400)
.
Link to the original text: https:// Wang Honglin's research group recruits postdoctoral fellows all the year round.
If you are interested, please contact: honglin.
wang@sjtu.
edu.
cn
